Preview

Российский журнал детской гематологии и онкологии (РЖДГиО)

Расширенный поиск

Таргетные препараты в лечении острых миелоидных лейкозов у детей

https://doi.org/10.21682/2311-1267-2020-7-3-78-85

Полный текст:

Аннотация

Возможности современной полихимиотерапии острых миелоидных лейкозов (ОМЛ) достигли своего предела, позволив получить общую выживаемость у 70 % больных. Дальнейшая эскалация химиотерапевтических режимов невозможна, поскольку сопряжена с крайне высокой токсичностью и риском развития жизнеугрожающих осложнений. Совершенствование программного лечения ОМЛ сопряжено с клиническим использованием достижений молекулярной биологии, иммунологии и цитогенетики опухолевой клетки. Исследования в области фундаментальной онкологии позволили выявить ключевые этапы лейкозогенеза и определить таргетные (молекулярно-направленные) пути воздействия в лечении ОМЛ.

Об авторах

Г. З. Серегин
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия

Врач-ординатор НИИ детской онкологии и гематологии

115478, Москва, Каширское шоссе, 23



А. В. Лифшиц
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России
Россия

Студентка 6-го курса педиатрического факультета

117997, Москва, ул. Островитянова, 1



Т. Т. Валиев
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия

Тимур Теймуразович Валиев, доктор медицинских наук, заведующий детским отделением химиотерапии гемобластозов отдела гематологии и трансплантации костного мозга НМИЦ онкологии им. Н.Н. Блохина, профессор кафедры детской онкологии РМАНПО

115478, Москва, Каширское шоссе, 23, 

125993, Москва, ул. Баррикадная, 2/1, стр. 1



Список литературы

1. Махачева Ф.А., Валиев Т.Т. Лечение острых миелоидных лейкозов у детей: современный взгляд на проблему. Онкогематология 2020;15(1):31–48. doi: 10.17650/1818-8346-2020-15-1-00-00.

2. Rasche M., Zimmermann M., Borschel L., Bourquin J.P., Dworzak M., Klingebiel T., Lehrnbecher T., Creutzig U., Klusmann J.H., Reinhardt D. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 2018;32(10):2167–77. doi: 10.1038/s41375-018-0071-7.

3. Bolouri H., Farrar J.E., Triche T. Jr, Ries R.E., Lim E.L., Alonzo T.A., Ma Y., Moore R., Mungall A.J., Marra M.A., Zhang J., Ma X., Liu Y., Liu Y., Auvil J., Davidsen T.M., Gesuwan P., Hermida L.C., Salhia B., Capone S., Meshinchi S. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and agespecific mutational interactions. Nat Med 2018;24:103–12. doi: 10.1038/nm.4439.

4. Chen J., Glasser C.L. New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML). Children 2020;7(2):12. doi: 10.3390/children7020012.

5. Gamis A.S., Alonzo T.A., Meshinchi S., Sung L., Gerbing R.B., Raimondi S.C., Hirsch B.A., Kahwash S.B., Heerema-McKenney A., Winter L., Glick K., Davies S.M., Byron P., Smith F.O., Aplenc R. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol 2014;32(27):3021–32. doi: 10.1200/JCO.2014.55.3628.

6. Walter R.B. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs 2018;27:339–48. doi: 10.1080/13543784.2018.1452911.

7. Raza A., Jurcic J.G., Roboz G.J., Maris M., Stephenson J.J., Wood B.L., Feldman E.J., Galili N., Grove L.E., Drachman J.G., Sievers E.L. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymph 2009;50(8):1336–44. doi: 10.1080/10428190903050013.

8. Feldman E.J., Brandwein J., Stone R., Kalaycio M., Moore J., OʼConnor J., Wedel N., Roboz G.J., Miller C., Chopra R., Jurcic J.C., Brown R., Ehmann W.C., Schulman P., Frankel S.R., DeAngelo D., Scheinberg D. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia. J Clin Oncol 2005;23(18):4110–6. doi: 10.1200/JCO.2005.09.133.

9. Fathi A.T., Erba H.P., Lancet J.E., Stein E.M., Ravandi F., Faderl S., Walter R.B., Advani A.S., DeAngelo D.J., Kovacsovics T.J., Jillella A., Bixby D., Levy M.Y., OʼMeara M.M., Ho P.A., Voellinger J., Stein A.S. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 2018;132(11):1125–33. doi: 10.1182/blood-2018-03-841171.

10. Stein E.M., Walter R.B., Erba H.P., Fathi A.T., Advani A.S., Lancet J.E., Ravandi F., Kovacsovics T., DeAngelo D.J., Bixby D., Faderl S., Jillella A.P., Ho P.A., OʼMeara M.M., Zhao B., Biddle-Snead C., Stein A.S. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood 2018;131(4):387–96. doi: 10.1182/blood-2017-06-789800.

11. Cooper T.M., Franklin J., Gerbing R.B., Alonzo T.A., Hurwitz C., Raimondi S.C., Hirsch B., Smith F.O., Mathew P., Arceci R.J., Feusner J., Iannone R., Lavey R.S., Meshinchi S., Gamis A. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia. Cancer 2012;118:761–9. doi: 10.1002/cncr.26190.

12. Norsworthy K.J., Ko C.W., Lee J.E., Liu J., John C.S., Przepiorka D., Farrell A.T., Pazdur R. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. Oncologist 2018;23(9):1103–8. doi: 10.1634/theoncologist.2017-0604.

13. Mercher T., Schwaller J. Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. Front Pediatr 2019;7:401. doi:10.3389/fped.2019.00401.

14. Sexauer A.N., Tasian S.K. Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia. Front Pediatr 2017;5:248. doi: 10.3389/fped.2017.00248.

15. Meshinchi S., Alonzo T.A., Stirewalt D.L., Zwaan M., Zimmerman M., Reinhardt D., Kaspers G.J., Heerema N.A., Gerbing R., Lange B.J., Radich J.P. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006;108(12):3654–61. doi: 10.1182/blood-2006-03-009233.

16. Park D., Kim M., Kim Y., Han K., Lee J.W. Molecular Features of Three Children Diagnosed With Early T-Cell Precursor Acute Lymphoblastic Leukemia. Ann Lab Med 2016;36(4):384–6. doi: 10.3343/alm.2016.36.4.384.

17. Manara E., Basso G., Zampini M., Buldini B., Tregnago C., Rondelli R., Masetti R., Bisio V., Frison M., Polato K., Cazzaniga G., Menna G., Fagioli F., Merli P., Biondi A., Pession A., Locatelli F., Pigazzi M. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia 2017;31:18–25. doi: 10.1038/leu.2016.177.

18. Locatelli F., Masetti R., Rondelli R., Zecca M., Fagioli F., Rovelli A., Messina C., Lanino E., Bertaina A., Favre C., Giorgiani G., Ripaldi M., Ziino O., Palumbo G., Pillon M., Pession A., Rutella S., Prete A. Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study. Bone Marrow Transplant 2015;50:181–8. doi: 10.1038/bmt.2014.246.

19. Cloos J., Goemans B.F., Hess C.J., van Oostveen J.W., Waisfisz Q., Corthals S., de Lange D., Boeckx N., Hählen K., Reinhardt D., Creutzig U., Schuurhuis G.J., Zwaan Ch.M., Kaspers G.J.L. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006;20:1217–20. doi: 10.1038/sj.leu.2404246.

20. Papaemmanuil E., Gerstung M., Bullinger L., Gaidzik V.I., Paschka P., Roberts N.D., Potter N.E., Heuser M., Thol F., Bolli N., Gundem G., Van Loo P., Martincorena I., Ganly P., Mudie L., McLaren S., OʼMeara S., Raine K., Jones D.R., Teague J.W., Campbell P.J. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016;374(23):2209–21. doi: 10.1056/NEJMoa1516192.

21. Inaba H., Rubnitz J.E., Coustan-Smith E., Li L., Furmanski B.D., Mascara G.P., Heym K.M., Christensen R., Onciu M., Shurtleff S.A., Pounds S.B., Pui C.H., Ribeiro R.C., Campana D., Baker S.D. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011;29(24):3293–300. doi: 10.1200/JCO.2011.34.7427.

22. Widemann B.C., Kim A., Fox E., Baruchel S., Adamson P.C., Ingle A.M., Glade Bender J., Burke M., Weigel B., Stempak D., Balis F.M., Blaney S.M. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Childrenʼs Oncology Group Phase I Consortium report. Clin Cancer Res 2012;18(21):6011–22. doi: 10.1158/1078-0432.CCR-11-3284.

23. Baker S.D., Zimmerman E.I., Wang Y.-D., Orwick S., Zatechka D.S., Buaboonnam J., Neale G.A., Olsen S.R., Enemark E.J., Shurtleff S., Rubnitz J.E., Mullighan C.G., Inaba H. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res 2013;19(20):5758–68. doi: 10.1158/1078-0432.CCR-13-1323.

24. Stone R.M., Mandrekar S.J., Sanford B.L., Laumann K., Geyer S., Bloomfield C.D., Thiede C., Prior T.W., Döhner K., Marcucci G., Lo-Coco F., Klisovic R.B., Wei A., Sierra J., Sanz M.A., Brandwein J.M., de Witte T., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Krauter J., Schlenk R.F., Ganser A., Serve H., Ehninger G., Amadori S., Larson R.A., Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 2017;377(5):454–64. doi: 10.1056/NEJMoa1614359.

25. Zwaan C.M., Söderhäll S., Brethon B., Luciani M., Rizzari C., Stam R.W., Besse E., Dutreix C., Fagioli F., Ho P.A., Dufour C., Pieters R. A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia. Br J Haematol 2019;185:623–7. doi: 10.1111/bjh.15593.

26. Cooper T.M., Cassar J., Eckroth E., Malvar J., Sposto R., Gaynon P., Chang B.H., Gore L., August K., Pollard J.A., DuBois S.G., Silverman L.B., Oesterheld J., Gammon G., Magoon D., Annesley C., Brown P.A. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res 2016;22(16):4014–22. doi: 10.1158/1078-0432.CCR15-1998.

27. Zimmerman E.I., Turner D.C., Buaboonnam J., Hu S., Orwick S., Roberts M.S., Janke L.J., Ramachandran A., Stewart C.F., Inaba H., Baker S.D. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 2013;122(22):3607–15. doi: 10.1182/blood-2013-07-513044.

28. Zhao J., Song Y., Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomark Res 2019;7:19. doi: 10.1186/s40364-019-0170-2.

29. Liang J., Wu Y.L., Chen B.J., Zhang W., Tanaka Y., Sugiyama H. The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci 2013;9(5):435–43. doi: 10.7150/ijbs.6087.

30. Lin S., Mulloy J.C., Goyama S. RUNX1-ETO leukemia. Adv Exp Med Biol 2017;962:151–73. doi:10.1007/978-981-10-3233-2-11.

31. Pui C., Carroll W.L., Meshinchi S., Arceci R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29(5):551–65. doi: 10.1200/JCO.2010.30.7405.

32. Pession A., Masetti R., Rizzari C., Putti C., Casale F., Fagioli F., Luciani M., Nigro L.L., Menna G., Micalizzi C., Santoro N., Testi A.M., Zecca M., Biondi A., Pigazzi M., Rutella S., Rondelli R., Basso G., Locatelli F. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013;122:170–8. doi: 10.1182/blood-2013-03-491621.

33. Gibson B.E.S., Webb D.K.H., Howman A.J., De Graaf S.S.N., Harrison C.J., Wheatley K. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Brit J Haematol 2011;155(3):366–76. doi: 10.1111/j.1365-2141.2011.08851.x.

34. Ustun C., Morgan E., Moodie E., Pullarkat S., Yeung C., BroesbyOlsen S., Ohgami R., Kim Y., Sperr W., Vestergaard H., Chen D., Kluin P.M., Dolan M., Mrózek K., Czuchlewski D., Horny H.P., George T.I., Kristensen T.K., Ku N.K., Yi C.A., Borthakur G. Corebinding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). Cancer Med 2018;7(9):4447–55. doi: 10.1002/cam4.1733.

35. Wang Y., Zhao L., Wu C., Liu P., Shi L., Liang Y., Xiong S., Mi J., Chen Z., Ren R., Chen S. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011;108(6):2450–5. doi: 10.1073/pnas.1019625108.

36. Manara E., Bisio V., Masetti R., Beqiri V., Rondelli R., Menna G., Micalizzi C., Santoro N., Locatelli F., Basso G., Pigazzi M. Corebinding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 2014;28(5):1132–4. doi: 10.1038/leu.2013.339.

37. Paschka P., Schlenk R.F., Weber D., Benner A., Bullinger L., Heuser M., Gaidzik V., Thol F., Agrawal M., Teleanu V., Lübbert M., Fiedler W., Radsak M., Krauter J., Horst H.-A., Greil R., Mayer K., Kündgen A., Martens U., Heil G., Salih H.R., Hertenstein B., Schwänen C., Wulf G., Lange E., Pfreundschuh M., Ringhoffer M., Girschikofsky M., Heinicke T., Kraemer D., Göhring G., Ganser A., Döhner K., Döhner H. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia ‒ results of the AMLSG 11-08 trial. Leukemia 2018;32:1621–30. doi: 10.1038/s41375-018-0129-6.

38. Briscoe J., Thérond P. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 2013;14:416–29. doi: 10.1038/nrm3598.

39. Campbell V., Copland M. Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning 2015;8:27–38. doi: 10.2147/SCCAA.S58613.

40. Martinelli G., Oehler V.G., Papayannidis C., Courtney R., Shaik M.N., Zhang X., OʼConnell A., McLachlan K.R., Zheng X., Radich J., Baccarani M., Kantarjian H.M., Levin W.J., Cortes J.E., Jamieson C. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol 2015;2:e339–46. doi: 10.1016/S2352-3026(15)00096-4.

41. Cortes J.E., Heidel F.H., Hellmann A., Fiedler W., Smith B.D., Robak T., Montesinos P., Pollyea D.A., Des Jardins P., Ottmann O., Ma W.W., Shaik M.N., Laird A.D., Zeremski M., O’Connell A., Chan G., Heuser M. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 2019;33(2):379–89. doi: 10.1038/s41375-018-0312-9.

42. Gruber T.A., Gedman A.L., Zhang J., Koss C.S., Marada S., Huy Q.T., Chen S.C., Su X., Ogden S.K., Dang J., Wu G., Gupta V., Andersson A.K., Pounds S., Shi L., Easton J., Barbato M.I., Mulder H.L., Manne J., Wang J., Rusch M., Ranade S., Ganti R., Parker M., Ma J., Radtke I., Ding L., Cazzaniga G., Biondi A., Kornblau S.M., Ravandi F., Kantarjian H., Nimer S.D., Döhner K., Döhner H., Ley T.J., Ballerini P., Shurtleff S., Tomizawa D., Adachi S., Hayashi Y., Tawa A., Shih L.-Y., Liang D.-C., Rubnitz J.E., Pui C.-H., Mardis E.R., Wilson R.K., Downing J.R. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 2012;22(5):683–97. doi: 10.1016/j.ccr.2012.10.007.

43. Masetti R., Pigazzi M., Togni M., Astolfi A., Indio V., Manara E., Casadio R., Pession A., Basso G., Locatelli F. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood 2013;121(17):3469–72. doi: 10.1182/blood-2012-11-469825.

44. Masetti R., Bertuccio S.N., Pession A., Locatelli F. CBFA2T3-GLIS2positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol 2019;184(3):337–47. doi: 10.1111/bjh.15725.

45. Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A., Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M., Pigazzi M., Maria Martelli A., Basso G., Locatelli F., Pession A. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. J Hematol Oncol 2017;10(1):26. doi: 10.1186/s13045-017-0396-0.

46. Thiollier C., Lopez C.K., Gerby B., Ignacimouttou C., Poglio S., Duffourd Y., Guégan J., Rivera-Munoz P., Bluteau O., Mabialah V., Diop M., Wen Q., Petit A., Bauchet A.L., Reinhardt D., Bornhauser B., Gautheret D., Lecluse Y., Landman-Parker J., Radford I., Vainchenker W., Dastugue N., de Botton S., Dessen P., Bourquin J.-P., Crispino J.D., Ballerini P., Bernard O.A., Pflumio F., Mercher T. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med 2012;209(11):2017–31. doi: 10.1084/jem.20121343.

47. . Mosse Y.P., Fox E., Teachey D.T., Reid J.M., Sagfren S.L., Carol H., Lock R.B., Houghton P.J., Smith M.A., Hall D.C., Barkauskas D.A., Krailo M., Voss S.D., Berg S.L., Blaney S., Weigel B.J. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Childrenʼs Oncology Group Phase I and Pilot Consortium (ADVL0921) Clin Cancer Res 2019;25(11):3229‒38. doi: 10.1158/1078-0432.CCR-18-2675.

48. Juárez-Salcedo L.M., Desai V., Dalia S. Venetoclax: evidence to date and clinical potential. Drugs Context 2019;8:212574. doi: 10.7573/dic.212574.

49. Karol S.E., Alexander T., Das Gupta S., Pounds S.B., Canavera K., Klco J.M., Lacayo N.J., Pui C.-H., Opferman J.T., Rubnitz J.E. Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia. J Clin Oncol 2019;37:15. doi: 10.1200/JCO.2019.37.15_suppl.10004

50. Masetti R., Vendemini F., Zama D., Biagi C., Pession A., Locatelli F. Acute myeloid leukemia in infants: biology and treatment. Front Pediatr 2015;3:37. doi: 10.3389/fped.2015.00037.

51. . Winters A.C., Bernt K.M. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr 2017;5:4. doi: 10.3389/fped.2017.00004.

52. Steger D.J., Lefterova M.I., Ying L., Stonestrom A.J., Schupp M., Zhuo D., Vakoc A.L., Kim J.E., Chen J., Lazar M.A., Blobel G.A., Vakoc C.R. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol 2008;28(8):2825–39. doi: 10.1128/MCB.02076-07.

53. Daigle S.R., Olhava E.J., Therkelsen C.A., Basavapathruni A., Jin L., Boriack-Sjodin P.A., Allain C.J., Klaus C.R., Raimondi A., Scott M.P., Waters N.J., Chesworth R., Moyer M.P., Copeland R.A., Richon V.M., Pollock R.M. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013;122(6):1017–25. doi: 10.1182/blood-2013-04-497644.

54. Stein E.M., Garcia-Manero G., Rizzieri D.A., Tibes R., Berdeja J.G., Savona M.R., Jongen-Lavrenic M., Altman J.K., Thomson B., Blakemore S.J., Daigle S.R., Waters N.J., Suttle A.B., Clawson A., Pollock R., Krivtsov A., Armstrong S.A., DiMartino J., Hedrick E., Löwenberg B., Tallman M.S. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 2018;131(24):2661–9. doi: 10.1182/blood-2017-12-818948.


Для цитирования:


Серегин Г.З., Лифшиц А.В., Валиев Т.Т. Таргетные препараты в лечении острых миелоидных лейкозов у детей. Российский журнал детской гематологии и онкологии (РЖДГиО). 2020;7(3):78-85. https://doi.org/10.21682/2311-1267-2020-7-3-78-85

For citation:


Seregin G.Z., Lifshits A.V., Valiev T.T. Targeted drugs in the treatment of acute myeloid leukemia in children. Russian Journal of Pediatric Hematology and Oncology. 2020;7(3):78-85. (In Russ.) https://doi.org/10.21682/2311-1267-2020-7-3-78-85

Просмотров: 43


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2311-1267 (Print)
ISSN 2413-5496 (Online)